BB Biotech (BION)

Currency in CHF

Last close As at 30/03/2023

CHF50.00

−0.10 (−0.20%)

Market capitalisation

CHF2,920m

BB Biotech, a Switzerland-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotech Index (in CHF) but managed on a bottom-up basis, with a focused c 20–35 stock portfolio.

Latest Insights

View More

Investment Companies

BB Biotech — Picking growth at good value

Investment Companies

BB Biotech – executive interview

Investment Companies

BB Biotech — Great valuation potential

Investment Companies

BB Biotech – executive interview

Equity Analyst

Joanne Collins

Joanne Collins

Analyst, Investment Trusts

Key Management

  • Claude Mikkelsen

    Director of IR

  • Daniel Koller

    Head of investment management

  • Dr Silvia Siegfried-Schanz

    Director of IR

  • Erich Hunziker

    Chairman

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (7.9) (9.6) (21.6)
Relative (5.7) (9.8) (12.0)
52 week high/low CHF67.7/CHF50.0

Overview

According to BB Biotech’s (BION’s) investment team, the biotech industry remains in a very good position. Following a sell-off in the last two years, valuations are still close to the levels seen three years ago, reflecting ongoing challenges and despite the fundamental industry strength. In the sector, BION is differentiated from the Nasdaq Biotechnology Index by its concentrated portfolio (c 30 stocks). The investment team anticipates that 2023 will include multiple catalysts for the sector and for BION portfolio companies, including product launches, important clinical trial results, licensing deals and renewed M&A activity. During 2022 the investment manager, Bellevue Asset Management, strengthened the investment team with three new members (two data scientists and one neurologist).

Investment Companies

BB Biotech — Update 27 February 2017

Investment Companies

Bitesize Briefings – BB Biotech

Investment Companies

BB Biotech AG — Update 8 February 2016